title: New treatment of neonatal pulmonary hemorrhage with hemocoagulase in addition to mechanical ventilation.
abstract: OBJECTIVE
  To investigate the effect of a new treatment for neonatal pulmonary hemorrhage with hemocoagulase in addition to mechanical ventilation.
  
  
  METHODS
  Forty-eight newborn infants with pulmonary hemorrhage were included and divided randomly into 2 groups. Among them, 28 patients were treated with hemocoagulase in addition to mechanical ventilation, and the other 20 neonates served as controls and were treated with mechanical ventilation only.
  
  
  RESULTS
  Both the length of pulmonary hemorrhage and the duration of mechanical ventilation in the survivors were significantly shortened in the infants treated with hemocoagulase in addition to mechanical ventilation as compared to controls (p < 0.05). Moreover, all infants that were unable to remain in the neonatal intensive care unit died after discharge, and when their outcome was estimated as non-survivors, the mortality in the patients with this new treatment was 39.3% (11/28), which was significantly lower than in controls (75.0%, 15/20; p < 0.05). When the discharged infants were not included in the statistics, the mortality in the hemocoagulase group was 10.7% (3/28), which was also significantly lower than in controls (40.0%, 8/20; p < 0.05).
  
  
  CONCLUSIONS
  The new treatment with hemocoagulase in addition to mechanical ventilation is effective in newborn infants with pulmonary hemorrhage.
authors.affiliation: Department of Pediatrics, Research Institute of Surgery and Daping Hospital, Third Military Medical University, Chongqing, China. petshi530@hotmail.com
authors.forename: Yuan
authors.initials: Y
authors.lastname: Shi
authors.forename: Shifang
authors.initials: S
authors.lastname: Tang
authors.forename: Huangqiang
authors.initials: H
authors.lastname: Li
authors.forename: Jinning
authors.initials: J
authors.lastname: Zhao
authors.forename: Feng
authors.initials: F
authors.lastname: Pan
mesh_terms: D012103:Batroxobin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D008171:Lung Diseases / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D012121:Respiration, Artificial; D016896:Treatment Outcome
chemical_list: D006490:Hemostatics; D012103:Batroxobin